Published in Lancet Infect Dis on April 24, 2014
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis (2016) 2.08
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg (2016) 1.55
Antibiotic stewardship in the intensive care unit. Crit Care (2014) 1.18
Burn wound healing and treatment: review and advancements. Crit Care (2015) 1.17
Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev (2017) 1.15
Therapeutic drug monitoring of antibiotics. Lancet Infect Dis (2014) 1.07
Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother (2016) 0.99
How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? BMC Infect Dis (2014) 0.95
Advances in antibiotic therapy in the critically ill. Crit Care (2016) 0.94
Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. Antimicrob Agents Chemother (2015) 0.86
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol (2015) 0.84
Pseudomonas aeruginosa ventilator-associated pneumonia management. Infect Drug Resist (2016) 0.83
Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol (2015) 0.80
Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients. Antimicrob Agents Chemother (2014) 0.79
Piperacillin concentration in relation to therapeutic range in critically ill patients - a prospective observational study. Crit Care (2016) 0.79
Estimation of creatinine clearance using plasma creatinine or cystatin C: a secondary analysis of two pharmacokinetic studies in surgical ICU patients. BMC Anesthesiol (2015) 0.78
Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. Antimicrob Agents Chemother (2014) 0.78
Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab (2016) 0.78
Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis (2015) 0.78
Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. Antimicrob Agents Chemother (2015) 0.78
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment based on Renal Function. Antimicrob Agents Chemother (2016) 0.78
Substantial targeting advantage achieved by pulmonary administration of colistin methanesulfonate: Insights from a large animal model. Antimicrob Agents Chemother (2016) 0.77
SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. BMC Infect Dis (2016) 0.77
In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis. Antimicrob Agents Chemother (2015) 0.76
Therapeutic Drug Monitoring of Continuous Infusion Doripenem in a Pediatric Patient on Continuous Renal Replacement Therapy. J Pediatr Pharmacol Ther (2017) 0.75
We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how? Crit Care (2016) 0.75
Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT. Clin J Am Soc Nephrol (2016) 0.75
Penetration of ciprofloxacin and amikacin into the alveolar epithelial lining fluid of rats with pulmonary fibrosis. Antimicrob Agents Chemother (2017) 0.75
Therapeutic drug monitoring of antibiotics--author's reply. Lancet Infect Dis (2014) 0.75
Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory. Clin Microbiol Rev (2016) 0.75
Simultaneous Determination of Eight β-Lactam Antibiotics, Amoxicillin, Cefazolin, Cefepime, Cefotaxime, Ceftazidime, Cloxacillin, Oxacillin, and Piperacillin, in Human Plasma by Using Ultra-High-Performance Liquid Chromatography with Ultraviolet Detection. Antimicrob Agents Chemother (2016) 0.75
Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? Crit Care (2016) 0.75
Outcome Assessment of Critical Care Pharmacist Services. Hosp Pharm (2016) 0.75
Pharmacokinetics of Anidulafungin in critically ill patients in the Intensive Care Unit with suspected or proven invasive fungal infections. Antimicrob Agents Chemother (2016) 0.75
Comparative evaluation of the predictive performance of three different structural population pharmacokinetic models to predict future voriconazole concentrations. Antimicrob Agents Chemother (2016) 0.75
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrob Agents Chemother (2017) 0.75
Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients. Antimicrob Agents Chemother (2016) 0.75
Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn's Disease. J Pediatr Gastroenterol Nutr (2017) 0.75
Understanding PK/PD. Intensive Care Med (2015) 0.75
Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients. Antimicrob Agents Chemother (2017) 0.75
[Antibiotic stewardship : A programmatic approach to improved antimicrobial management]. Unfallchirurg (2017) 0.75
Suppressive drug combinations and their potential to combat antibiotic resistance. J Antibiot (Tokyo) (2017) 0.75
Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. Clin Pharmacokinet (2017) 0.75
Are standard doses of piperacillin in piperacillin/tazobactam regimens adequate for the management of febrile neutropenia? Answers from population pharmacokinetic modelling and Monte Carlo simulations. Antimicrob Agents Chemother (2017) 0.75
Intensive versus conventional glucose control in critically ill patients. N Engl J Med (2009) 26.30
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med (2006) 23.62
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20
A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med (2004) 12.79
International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57
Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med (2007) 10.02
Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med (2009) 9.77
Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med (2012) 9.19
Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis (1988) 7.50
Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest (1999) 7.40
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis (1987) 5.63
Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis (2009) 5.52
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis (2006) 5.34
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol (2004) 5.19
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA (1998) 4.99
Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am (2003) 4.16
A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant (2007) 4.11
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis (2014) 3.99
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet (2004) 3.92
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J (1996) 3.59
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest (2003) 3.31
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis (2007) 3.30
Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol (2007) 3.17
Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med (2009) 3.09
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis (2012) 2.88
In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother (2004) 2.88
Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care (2008) 2.74
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med (1989) 2.56
Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med (2003) 2.40
In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother (2000) 2.39
Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis (2003) 2.30
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother (2001) 2.23
A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med (2009) 2.17
Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis (2005) 2.10
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med (2012) 2.04
Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis (2007) 1.92
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents (2008) 1.92
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care (2011) 1.91
Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis (2005) 1.89
Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med (2005) 1.88
Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother (2001) 1.87
Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother (2009) 1.83
Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.81
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.77
Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med (2008) 1.75
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet (2003) 1.70
The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis (2005) 1.68
Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis (2003) 1.67
Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother (2002) 1.64
Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med (2013) 1.63
Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother (2003) 1.61
Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother (2004) 1.54
Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother (1993) 1.52
First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents (2009) 1.52
Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med (2001) 1.50
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care (2011) 1.48
Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother (2007) 1.43
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents (2010) 1.43
fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother (2010) 1.42
Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect Control Hosp Epidemiol (2006) 1.42
Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis (2004) 1.41
Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother (2009) 1.40
Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother (2006) 1.39
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet (2011) 1.39
A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother (1996) 1.36
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother (2011) 1.35
Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med J (2011) 1.33
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother (2007) 1.33
Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology (2012) 1.30
Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother (2004) 1.30
Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet (2011) 1.30
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother (2005) 1.24
Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother (2004) 1.23
Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med (2004) 1.23
Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med (2009) 1.23
Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother (2013) 1.21
Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother (2011) 1.21
Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care (1993) 1.21
Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg (2003) 1.20
Vital organ blood flow during hyperdynamic sepsis. Chest (2003) 1.19
Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother (2009) 1.17
Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother (2003) 1.17
Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol (2011) 1.17
Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother (2006) 1.17
Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Crit Care Med (2009) 1.16
The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother (2001) 1.15
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother (2012) 1.14
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents (2001) 1.13
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother (2011) 1.12
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother (2010) 1.11
Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother (1999) 1.11
Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations. J Antimicrob Chemother (1996) 1.11
Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother (2010) 1.10
Immunotherapy of sepsis. Lancet Infect Dis (2001) 1.10
Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis (2005) 1.10
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother (2006) 1.09
Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med (2002) 1.09
Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother (2009) 1.07
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis (2014) 1.80
Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother (2014) 1.19
Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother (2015) 0.87
Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. J Antimicrob Chemother (2015) 0.81
Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. Clin Pharmacokinet (2016) 0.78
Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. J Antimicrob Chemother (2015) 0.78
Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. J Clin Pharmacol (2016) 0.77
Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). Infect Dis Ther (2014) 0.75
Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development. Infect Dis Rep (2017) 0.75
Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis. J Antimicrob Chemother (2022) 0.75
An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. J Infect Chemother (2015) 0.75
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents (2016) 0.75
Tissue penetration and exposure of cefepime in patients with diabetic foot infections. Int J Antimicrob Agents (2016) 0.75
Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents (2016) 0.75
Defining the impact of severity of illness on time above the MIC threshold for cefepime in gram-negative bacteremia: a 'goldilocks' window. Int J Antimicrob Agents (2017) 0.75
Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis. Int J Antimicrob Agents (2015) 0.75